- Home
- INZY vs FSFG Comparison
INZY vs FSFG Comparison
Compare INZY & FSFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- FSFG
- Stock Information
- Founded
- INZY 2015
- FSFG 2008
- Country
- INZY United States
- FSFG United States
- Employees
- INZY N/A
- FSFG N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- FSFG Savings Institutions
- Sector
- INZY Health Care
- FSFG Finance
- Exchange
- INZY Nasdaq
- FSFG Nasdaq
- Market Cap
- INZY 188.2M
- FSFG N/A
- IPO Year
- INZY 2020
- FSFG 2008
- Fundamental
- Price
- INZY $1.51
- FSFG $24.32
- Analyst Decision
- INZY Strong Buy
- FSFG Buy
- Analyst Count
- INZY 8
- FSFG 1
- Target Price
- INZY $17.75
- FSFG $31.00
- AVG Volume (30 Days)
- INZY 639.1K
- FSFG 13.4K
- Earning Date
- INZY 11-05-2024
- FSFG 01-28-2025
- Dividend Yield
- INZY N/A
- FSFG 2.44%
- EPS Growth
- INZY N/A
- FSFG 66.39
- EPS
- INZY N/A
- FSFG 1.98
- Revenue
- INZY N/A
- FSFG $68,091,000.00
- Revenue This Year
- INZY N/A
- FSFG N/A
- Revenue Next Year
- INZY N/A
- FSFG $2.77
- P/E Ratio
- INZY N/A
- FSFG $12.42
- Revenue Growth
- INZY N/A
- FSFG N/A
- 52 Week Low
- INZY $1.45
- FSFG $14.55
- 52 Week High
- INZY $7.80
- FSFG $30.94
- Technical
- Relative Strength Index (RSI)
- INZY 21.70
- FSFG 32.23
- Support Level
- INZY $2.68
- FSFG $25.25
- Resistance Level
- INZY $3.18
- FSFG $27.17
- Average True Range (ATR)
- INZY 0.28
- FSFG 0.81
- MACD
- INZY -0.12
- FSFG -0.16
- Stochastic Oscillator
- INZY 3.47
- FSFG 4.04
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.